{
  "id": 1577662,
  "title": "Oncoclínicas Q2 2026 slides: EBITDA turns positive despite revenue drop",
  "url": "https://urgent.news/2026/08/17/oncoclinicas-q2-2026-slides-ebitda-turns-positive-despite-revenue-drop",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-08-17T22:26:01.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/company-news/oncoclinicas-q2-2026-slides-ebitda-turns-positive-despite-revenue-drop-93CH-4864070"
  },
  "original_language": "en",
  "account": "Brazilian oncology provider Oncoclínicas reported improved financial performance in its second quarter of 2026, with positive adjusted EBITDA and operating cash flow despite a decline in revenue. The company's stock rose 29.87% to $1.00 following the presentation. The quarter was marked by a medication supply crisis, medication shortages, and one-time accounting charges. Despite a 25.9% drop in gross revenue to R$1,227.6 million, adjusted EBITDA turned positive at R$34.3 million, a 3.3% margin. Normalizing for the provision for loan losses, the adjusted EBITDA margin reached 9.5%. Operating cash flow turned positive at R$158.4 million, reflecting improved working capital management. Capital expenditures remained low at R$13.3 million, with a net debt of R$3.4 billion. The company's net loss for the quarter was R$275.3 million, but the trailing twelve-month adjusted net loss stood at R$1,350.8 million.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}